Global Immuno-oncology Drugs Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • Immuno-oncology Drugs market report explains the definition, types, applications, major countries, and major players of the Immuno-oncology Drugs market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Celgene Corporation

    • Celldex Therapeutics

    • AbbVie Inc

    • Hoffmann-La Roche AG

    • Aduro BioTech

    • Prometheus Therapeutics & Diagnostics

    • AstraZeneca, Plc

    • Novartis International AG

    • Bavarian Nordic

    • Sanofi SA

    • Bristol-Myers Squibb

    • Merck & Co

    • EMD Serono Inc

    • ImmunoCellular Therapeutics

    • Eli Lilly and Company

    • Galena Biopharma

    • Amgen Inc

    • Gilead Sciences Inc

    • Incyte

    • Pfizer Inc

    • Johnson & Johnson

    By Type:

    • Immune Checkpoint Inhibitors

    • Monoclonal Antibodies

    • Cytokine-Based Immunotherapy

    • Cancer Vaccines

    • CAR-T Cell Therapy

    By End-User:

    • Hospitals

    • Pharmacies

    • Online Pharmacies

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Immuno-oncology Drugs Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Immuno-oncology Drugs Outlook to 2028- Original Forecasts

    • 2.2 Immuno-oncology Drugs Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Immuno-oncology Drugs Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Immuno-oncology Drugs Market- Recent Developments

    • 6.1 Immuno-oncology Drugs Market News and Developments

    • 6.2 Immuno-oncology Drugs Market Deals Landscape

    7 Immuno-oncology Drugs Raw Materials and Cost Structure Analysis

    • 7.1 Immuno-oncology Drugs Key Raw Materials

    • 7.2 Immuno-oncology Drugs Price Trend of Key Raw Materials

    • 7.3 Immuno-oncology Drugs Key Suppliers of Raw Materials

    • 7.4 Immuno-oncology Drugs Market Concentration Rate of Raw Materials

    • 7.5 Immuno-oncology Drugs Cost Structure Analysis

      • 7.5.1 Immuno-oncology Drugs Raw Materials Analysis

      • 7.5.2 Immuno-oncology Drugs Labor Cost Analysis

      • 7.5.3 Immuno-oncology Drugs Manufacturing Expenses Analysis

    8 Global Immuno-oncology Drugs Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Immuno-oncology Drugs Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Immuno-oncology Drugs Export by Region (Top 10 Countries) (2017-2028)

    9 Global Immuno-oncology Drugs Market Outlook by Types and Applications to 2022

    • 9.1 Global Immuno-oncology Drugs Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Immune Checkpoint Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Cytokine-Based Immunotherapy Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Cancer Vaccines Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global CAR-T Cell Therapy Consumption and Growth Rate (2017-2022)

    • 9.2 Global Immuno-oncology Drugs Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospitals Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Pharmacies Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Online Pharmacies Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Immuno-oncology Drugs Market Analysis and Outlook till 2022

    • 10.1 Global Immuno-oncology Drugs Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Immuno-oncology Drugs Consumption (2017-2022)

      • 10.2.2 Canada Immuno-oncology Drugs Consumption (2017-2022)

      • 10.2.3 Mexico Immuno-oncology Drugs Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Immuno-oncology Drugs Consumption (2017-2022)

      • 10.3.2 UK Immuno-oncology Drugs Consumption (2017-2022)

      • 10.3.3 Spain Immuno-oncology Drugs Consumption (2017-2022)

      • 10.3.4 Belgium Immuno-oncology Drugs Consumption (2017-2022)

      • 10.3.5 France Immuno-oncology Drugs Consumption (2017-2022)

      • 10.3.6 Italy Immuno-oncology Drugs Consumption (2017-2022)

      • 10.3.7 Denmark Immuno-oncology Drugs Consumption (2017-2022)

      • 10.3.8 Finland Immuno-oncology Drugs Consumption (2017-2022)

      • 10.3.9 Norway Immuno-oncology Drugs Consumption (2017-2022)

      • 10.3.10 Sweden Immuno-oncology Drugs Consumption (2017-2022)

      • 10.3.11 Poland Immuno-oncology Drugs Consumption (2017-2022)

      • 10.3.12 Russia Immuno-oncology Drugs Consumption (2017-2022)

      • 10.3.13 Turkey Immuno-oncology Drugs Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Immuno-oncology Drugs Consumption (2017-2022)

      • 10.4.2 Japan Immuno-oncology Drugs Consumption (2017-2022)

      • 10.4.3 India Immuno-oncology Drugs Consumption (2017-2022)

      • 10.4.4 South Korea Immuno-oncology Drugs Consumption (2017-2022)

      • 10.4.5 Pakistan Immuno-oncology Drugs Consumption (2017-2022)

      • 10.4.6 Bangladesh Immuno-oncology Drugs Consumption (2017-2022)

      • 10.4.7 Indonesia Immuno-oncology Drugs Consumption (2017-2022)

      • 10.4.8 Thailand Immuno-oncology Drugs Consumption (2017-2022)

      • 10.4.9 Singapore Immuno-oncology Drugs Consumption (2017-2022)

      • 10.4.10 Malaysia Immuno-oncology Drugs Consumption (2017-2022)

      • 10.4.11 Philippines Immuno-oncology Drugs Consumption (2017-2022)

      • 10.4.12 Vietnam Immuno-oncology Drugs Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Immuno-oncology Drugs Consumption (2017-2022)

      • 10.5.2 Colombia Immuno-oncology Drugs Consumption (2017-2022)

      • 10.5.3 Chile Immuno-oncology Drugs Consumption (2017-2022)

      • 10.5.4 Argentina Immuno-oncology Drugs Consumption (2017-2022)

      • 10.5.5 Venezuela Immuno-oncology Drugs Consumption (2017-2022)

      • 10.5.6 Peru Immuno-oncology Drugs Consumption (2017-2022)

      • 10.5.7 Puerto Rico Immuno-oncology Drugs Consumption (2017-2022)

      • 10.5.8 Ecuador Immuno-oncology Drugs Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Immuno-oncology Drugs Consumption (2017-2022)

      • 10.6.2 Kuwait Immuno-oncology Drugs Consumption (2017-2022)

      • 10.6.3 Oman Immuno-oncology Drugs Consumption (2017-2022)

      • 10.6.4 Qatar Immuno-oncology Drugs Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Immuno-oncology Drugs Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Immuno-oncology Drugs Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Immuno-oncology Drugs Consumption (2017-2022)

      • 10.7.2 South Africa Immuno-oncology Drugs Consumption (2017-2022)

      • 10.7.3 Egypt Immuno-oncology Drugs Consumption (2017-2022)

      • 10.7.4 Algeria Immuno-oncology Drugs Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Immuno-oncology Drugs Consumption (2017-2022)

      • 10.8.2 New Zealand Immuno-oncology Drugs Consumption (2017-2022)

    11 Global Immuno-oncology Drugs Competitive Analysis

    • 11.1 Celgene Corporation

      • 11.1.1 Celgene Corporation Company Details

      • 11.1.2 Celgene Corporation Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Celgene Corporation Immuno-oncology Drugs Main Business and Markets Served

      • 11.1.4 Celgene Corporation Immuno-oncology Drugs Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Celldex Therapeutics

      • 11.2.1 Celldex Therapeutics Company Details

      • 11.2.2 Celldex Therapeutics Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Celldex Therapeutics Immuno-oncology Drugs Main Business and Markets Served

      • 11.2.4 Celldex Therapeutics Immuno-oncology Drugs Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 AbbVie Inc

      • 11.3.1 AbbVie Inc Company Details

      • 11.3.2 AbbVie Inc Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 AbbVie Inc Immuno-oncology Drugs Main Business and Markets Served

      • 11.3.4 AbbVie Inc Immuno-oncology Drugs Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Hoffmann-La Roche AG

      • 11.4.1 Hoffmann-La Roche AG Company Details

      • 11.4.2 Hoffmann-La Roche AG Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Hoffmann-La Roche AG Immuno-oncology Drugs Main Business and Markets Served

      • 11.4.4 Hoffmann-La Roche AG Immuno-oncology Drugs Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Aduro BioTech

      • 11.5.1 Aduro BioTech Company Details

      • 11.5.2 Aduro BioTech Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Aduro BioTech Immuno-oncology Drugs Main Business and Markets Served

      • 11.5.4 Aduro BioTech Immuno-oncology Drugs Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Prometheus Therapeutics & Diagnostics

      • 11.6.1 Prometheus Therapeutics & Diagnostics Company Details

      • 11.6.2 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Main Business and Markets Served

      • 11.6.4 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 AstraZeneca, Plc

      • 11.7.1 AstraZeneca, Plc Company Details

      • 11.7.2 AstraZeneca, Plc Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 AstraZeneca, Plc Immuno-oncology Drugs Main Business and Markets Served

      • 11.7.4 AstraZeneca, Plc Immuno-oncology Drugs Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Novartis International AG

      • 11.8.1 Novartis International AG Company Details

      • 11.8.2 Novartis International AG Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Novartis International AG Immuno-oncology Drugs Main Business and Markets Served

      • 11.8.4 Novartis International AG Immuno-oncology Drugs Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Bavarian Nordic

      • 11.9.1 Bavarian Nordic Company Details

      • 11.9.2 Bavarian Nordic Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Bavarian Nordic Immuno-oncology Drugs Main Business and Markets Served

      • 11.9.4 Bavarian Nordic Immuno-oncology Drugs Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 Sanofi SA

      • 11.10.1 Sanofi SA Company Details

      • 11.10.2 Sanofi SA Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 Sanofi SA Immuno-oncology Drugs Main Business and Markets Served

      • 11.10.4 Sanofi SA Immuno-oncology Drugs Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    • 11.11 Bristol-Myers Squibb

      • 11.11.1 Bristol-Myers Squibb Company Details

      • 11.11.2 Bristol-Myers Squibb Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.11.3 Bristol-Myers Squibb Immuno-oncology Drugs Main Business and Markets Served

      • 11.11.4 Bristol-Myers Squibb Immuno-oncology Drugs Product Portfolio

      • 11.11.5 Recent Research and Development Strategies

    • 11.12 Merck & Co

      • 11.12.1 Merck & Co Company Details

      • 11.12.2 Merck & Co Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.12.3 Merck & Co Immuno-oncology Drugs Main Business and Markets Served

      • 11.12.4 Merck & Co Immuno-oncology Drugs Product Portfolio

      • 11.12.5 Recent Research and Development Strategies

    • 11.13 EMD Serono Inc

      • 11.13.1 EMD Serono Inc Company Details

      • 11.13.2 EMD Serono Inc Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.13.3 EMD Serono Inc Immuno-oncology Drugs Main Business and Markets Served

      • 11.13.4 EMD Serono Inc Immuno-oncology Drugs Product Portfolio

      • 11.13.5 Recent Research and Development Strategies

    • 11.14 ImmunoCellular Therapeutics

      • 11.14.1 ImmunoCellular Therapeutics Company Details

      • 11.14.2 ImmunoCellular Therapeutics Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.14.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Main Business and Markets Served

      • 11.14.4 ImmunoCellular Therapeutics Immuno-oncology Drugs Product Portfolio

      • 11.14.5 Recent Research and Development Strategies

    • 11.15 Eli Lilly and Company

      • 11.15.1 Eli Lilly and Company Company Details

      • 11.15.2 Eli Lilly and Company Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.15.3 Eli Lilly and Company Immuno-oncology Drugs Main Business and Markets Served

      • 11.15.4 Eli Lilly and Company Immuno-oncology Drugs Product Portfolio

      • 11.15.5 Recent Research and Development Strategies

    • 11.16 Galena Biopharma

      • 11.16.1 Galena Biopharma Company Details

      • 11.16.2 Galena Biopharma Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.16.3 Galena Biopharma Immuno-oncology Drugs Main Business and Markets Served

      • 11.16.4 Galena Biopharma Immuno-oncology Drugs Product Portfolio

      • 11.16.5 Recent Research and Development Strategies

    • 11.17 Amgen Inc

      • 11.17.1 Amgen Inc Company Details

      • 11.17.2 Amgen Inc Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.17.3 Amgen Inc Immuno-oncology Drugs Main Business and Markets Served

      • 11.17.4 Amgen Inc Immuno-oncology Drugs Product Portfolio

      • 11.17.5 Recent Research and Development Strategies

    • 11.18 Gilead Sciences Inc

      • 11.18.1 Gilead Sciences Inc Company Details

      • 11.18.2 Gilead Sciences Inc Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.18.3 Gilead Sciences Inc Immuno-oncology Drugs Main Business and Markets Served

      • 11.18.4 Gilead Sciences Inc Immuno-oncology Drugs Product Portfolio

      • 11.18.5 Recent Research and Development Strategies

    • 11.19 Incyte

      • 11.19.1 Incyte Company Details

      • 11.19.2 Incyte Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.19.3 Incyte Immuno-oncology Drugs Main Business and Markets Served

      • 11.19.4 Incyte Immuno-oncology Drugs Product Portfolio

      • 11.19.5 Recent Research and Development Strategies

    • 11.20 Pfizer Inc

      • 11.20.1 Pfizer Inc Company Details

      • 11.20.2 Pfizer Inc Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.20.3 Pfizer Inc Immuno-oncology Drugs Main Business and Markets Served

      • 11.20.4 Pfizer Inc Immuno-oncology Drugs Product Portfolio

      • 11.20.5 Recent Research and Development Strategies

    • 11.21 Johnson & Johnson

      • 11.21.1 Johnson & Johnson Company Details

      • 11.21.2 Johnson & Johnson Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

      • 11.21.3 Johnson & Johnson Immuno-oncology Drugs Main Business and Markets Served

      • 11.21.4 Johnson & Johnson Immuno-oncology Drugs Product Portfolio

      • 11.21.5 Recent Research and Development Strategies

    12 Global Immuno-oncology Drugs Market Outlook by Types and Applications to 2028

    • 12.1 Global Immuno-oncology Drugs Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Immune Checkpoint Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Cytokine-Based Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Cancer Vaccines Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.5 Global CAR-T Cell Therapy Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Immuno-oncology Drugs Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Pharmacies Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Immuno-oncology Drugs Market Analysis and Outlook to 2028

    • 13.1 Global Immuno-oncology Drugs Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.2.2 Canada Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Immuno-oncology Drugs Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.3.2 UK Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.3.3 Spain Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.3.5 France Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.3.6 Italy Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.3.8 Finland Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.3.9 Norway Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.3.11 Poland Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.3.12 Russia Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Immuno-oncology Drugs Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.4.2 Japan Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.4.3 India Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Immuno-oncology Drugs Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.5.3 Chile Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.5.6 Peru Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Immuno-oncology Drugs Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.6.3 Oman Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Immuno-oncology Drugs Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Immuno-oncology Drugs Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Immuno-oncology Drugs Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Immuno-oncology Drugs Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Immuno-oncology Drugs

    • Figure of Immuno-oncology Drugs Picture

    • Table Global Immuno-oncology Drugs Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Immuno-oncology Drugs Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Immune Checkpoint Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Global Cytokine-Based Immunotherapy Consumption and Growth Rate (2017-2022)

    • Figure Global Cancer Vaccines Consumption and Growth Rate (2017-2022)

    • Figure Global CAR-T Cell Therapy Consumption and Growth Rate (2017-2022)

    • Figure Global Hospitals Consumption and Growth Rate (2017-2022)

    • Figure Global Pharmacies Consumption and Growth Rate (2017-2022)

    • Figure Global Online Pharmacies Consumption and Growth Rate (2017-2022)

    • Figure Global Immuno-oncology Drugs Consumption by Country (2017-2022)

    • Table North America Immuno-oncology Drugs Consumption by Country (2017-2022)

    • Figure United States Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Canada Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Mexico Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Table Europe Immuno-oncology Drugs Consumption by Country (2017-2022)

    • Figure Germany Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure UK Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Spain Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Belgium Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure France Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Italy Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Denmark Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Finland Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Norway Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Sweden Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Poland Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Russia Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Turkey Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Table APAC Immuno-oncology Drugs Consumption by Country (2017-2022)

    • Figure China Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Japan Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure India Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure South Korea Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Thailand Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Singapore Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Philippines Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Table South America Immuno-oncology Drugs Consumption by Country (2017-2022)

    • Figure Brazil Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Colombia Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Chile Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Argentina Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Peru Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Table GCC Immuno-oncology Drugs Consumption by Country (2017-2022)

    • Figure Bahrain Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Oman Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Qatar Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Table Africa Immuno-oncology Drugs Consumption by Country (2017-2022)

    • Figure Nigeria Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure South Africa Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Egypt Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure Algeria Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Table Oceania Immuno-oncology Drugs Consumption by Country (2017-2022)

    • Figure Australia Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Immuno-oncology Drugs Consumption and Growth Rate (2017-2022)

    • Table Celgene Corporation Company Details

    • Table Celgene Corporation Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celgene Corporation Immuno-oncology Drugs Main Business and Markets Served

    • Table Celgene Corporation Immuno-oncology Drugs Product Portfolio

    • Table Celldex Therapeutics Company Details

    • Table Celldex Therapeutics Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Celldex Therapeutics Immuno-oncology Drugs Main Business and Markets Served

    • Table Celldex Therapeutics Immuno-oncology Drugs Product Portfolio

    • Table AbbVie Inc Company Details

    • Table AbbVie Inc Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table AbbVie Inc Immuno-oncology Drugs Main Business and Markets Served

    • Table AbbVie Inc Immuno-oncology Drugs Product Portfolio

    • Table Hoffmann-La Roche AG Company Details

    • Table Hoffmann-La Roche AG Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Hoffmann-La Roche AG Immuno-oncology Drugs Main Business and Markets Served

    • Table Hoffmann-La Roche AG Immuno-oncology Drugs Product Portfolio

    • Table Aduro BioTech Company Details

    • Table Aduro BioTech Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Aduro BioTech Immuno-oncology Drugs Main Business and Markets Served

    • Table Aduro BioTech Immuno-oncology Drugs Product Portfolio

    • Table Prometheus Therapeutics & Diagnostics Company Details

    • Table Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Main Business and Markets Served

    • Table Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Portfolio

    • Table AstraZeneca, Plc Company Details

    • Table AstraZeneca, Plc Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table AstraZeneca, Plc Immuno-oncology Drugs Main Business and Markets Served

    • Table AstraZeneca, Plc Immuno-oncology Drugs Product Portfolio

    • Table Novartis International AG Company Details

    • Table Novartis International AG Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis International AG Immuno-oncology Drugs Main Business and Markets Served

    • Table Novartis International AG Immuno-oncology Drugs Product Portfolio

    • Table Bavarian Nordic Company Details

    • Table Bavarian Nordic Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bavarian Nordic Immuno-oncology Drugs Main Business and Markets Served

    • Table Bavarian Nordic Immuno-oncology Drugs Product Portfolio

    • Table Sanofi SA Company Details

    • Table Sanofi SA Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi SA Immuno-oncology Drugs Main Business and Markets Served

    • Table Sanofi SA Immuno-oncology Drugs Product Portfolio

    • Table Bristol-Myers Squibb Company Details

    • Table Bristol-Myers Squibb Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol-Myers Squibb Immuno-oncology Drugs Main Business and Markets Served

    • Table Bristol-Myers Squibb Immuno-oncology Drugs Product Portfolio

    • Table Merck & Co Company Details

    • Table Merck & Co Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck & Co Immuno-oncology Drugs Main Business and Markets Served

    • Table Merck & Co Immuno-oncology Drugs Product Portfolio

    • Table EMD Serono Inc Company Details

    • Table EMD Serono Inc Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table EMD Serono Inc Immuno-oncology Drugs Main Business and Markets Served

    • Table EMD Serono Inc Immuno-oncology Drugs Product Portfolio

    • Table ImmunoCellular Therapeutics Company Details

    • Table ImmunoCellular Therapeutics Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table ImmunoCellular Therapeutics Immuno-oncology Drugs Main Business and Markets Served

    • Table ImmunoCellular Therapeutics Immuno-oncology Drugs Product Portfolio

    • Table Eli Lilly and Company Company Details

    • Table Eli Lilly and Company Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly and Company Immuno-oncology Drugs Main Business and Markets Served

    • Table Eli Lilly and Company Immuno-oncology Drugs Product Portfolio

    • Table Galena Biopharma Company Details

    • Table Galena Biopharma Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Galena Biopharma Immuno-oncology Drugs Main Business and Markets Served

    • Table Galena Biopharma Immuno-oncology Drugs Product Portfolio

    • Table Amgen Inc Company Details

    • Table Amgen Inc Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Amgen Inc Immuno-oncology Drugs Main Business and Markets Served

    • Table Amgen Inc Immuno-oncology Drugs Product Portfolio

    • Table Gilead Sciences Inc Company Details

    • Table Gilead Sciences Inc Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gilead Sciences Inc Immuno-oncology Drugs Main Business and Markets Served

    • Table Gilead Sciences Inc Immuno-oncology Drugs Product Portfolio

    • Table Incyte Company Details

    • Table Incyte Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Incyte Immuno-oncology Drugs Main Business and Markets Served

    • Table Incyte Immuno-oncology Drugs Product Portfolio

    • Table Pfizer Inc Company Details

    • Table Pfizer Inc Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Pfizer Inc Immuno-oncology Drugs Main Business and Markets Served

    • Table Pfizer Inc Immuno-oncology Drugs Product Portfolio

    • Table Johnson & Johnson Company Details

    • Table Johnson & Johnson Immuno-oncology Drugs Sales, Price, Value and Gross Profit (2017-2022)

    • Table Johnson & Johnson Immuno-oncology Drugs Main Business and Markets Served

    • Table Johnson & Johnson Immuno-oncology Drugs Product Portfolio

    • Figure Global Immune Checkpoint Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Cytokine-Based Immunotherapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Cancer Vaccines Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global CAR-T Cell Therapy Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospitals Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Online Pharmacies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Immuno-oncology Drugs Consumption Forecast by Country (2022-2028)

    • Table North America Immuno-oncology Drugs Consumption Forecast by Country (2022-2028)

    • Figure United States Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Immuno-oncology Drugs Consumption Forecast by Country (2022-2028)

    • Figure Germany Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Immuno-oncology Drugs Consumption Forecast by Country (2022-2028)

    • Figure China Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Immuno-oncology Drugs Consumption Forecast by Country (2022-2028)

    • Figure Brazil Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Immuno-oncology Drugs Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Immuno-oncology Drugs Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Immuno-oncology Drugs Consumption Forecast by Country (2022-2028)

    • Figure Australia Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Immuno-oncology Drugs Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.